Bonadio RC, Divino PHA, Obando JSM, et al. - Patients with borderline or unresectable (B/U) liver metastases from colorectal cancer (CRC)—who were treated with conversion chemotherapy with the modified fluorouracil, leucovorin, and oxaliplatin (mFLOX) regimen followed by metastasectomy—were examined for their outcomes in this single-center retrospective analysis. Among 54 eligible patients for this work, 35 (64%) presented with more than four liver lesions, 16 (29%) presented with key vascular structure involvement, and 16 (29%) with biliary involvement. Researchers noted a high R0 resection rate and favorable survival outcomes in correlation with the treatment of B/U liver metastases from CRC with conversion chemotherapy using mFLOX regimen followed by surgical resection. For conversion chemotherapy, mFLOX is favored as a low-cost option among other options that have been proposed.